RT Journal Article
SR Electronic
T1 Emergence and Spread of the SARS-CoV-2 Omicron Variant in Alberta Communities Revealed by Wastewater Monitoring
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.07.22272055
DO 10.1101/2022.03.07.22272055
A1 Hubert, Casey R.J.
A1 Acosta, Nicole
A1 Waddell, Barbara J.
A1 Hasing, Maria E.
A1 Qiu, Yuanyuan
A1 Fuzzen, Meghan
A1 Harper, Nathanael B.J.
A1 Bautista, María A.
A1 Gao, Tiejun
A1 Papparis, Chloe
A1 Van Doorn, Jenn
A1 Du, Kristine
A1 Xiang, Kevin
A1 Chan, Leslie
A1 Vivas, Laura
A1 Pradhan, Puja
A1 McCalder, Janine
A1 Low, Kashtin
A1 England, Whitney E.
A1 Kuzma, Darina
A1 Conly, John
A1 Ryan, M. Cathryn
A1 Achari, Gopal
A1 Hu, Jia
A1 Cabaj, Jason L.
A1 Sikora, Chris
A1 Svenson, Larry
A1 Zelyas, Nathan
A1 Servos, Mark
A1 Meddings, Jon
A1 Hrudey, Steve E.
A1 Frankowski, Kevin
A1 Parkins, Michael D.
A1 Pang, Xiaoli (Lilly)
A1 Lee, Bonita E.
YR 2022
UL http://medrxiv.org/content/early/2022/03/10/2022.03.07.22272055.abstract
AB Wastewater monitoring of SARS-CoV-2 allows for early detection and monitoring of COVID-19 burden in communities and can track specific variants of concern. Targeted assays enabled relative proportions of SARS-CoV-2 Omicron and Delta variants to be determined across 30 municipalities covering >75% of the province of Alberta (pop. 4.5M) in Canada, from November 2021 to January 2022. Larger cities like Calgary and Edmonton exhibited a more rapid emergence of Omicron relative to smaller and more remote municipalities. Notable exceptions were Banff, a small international resort town, and Fort McMurray, a more remote northern city with a large fly-in worker population. The integrated wastewater signal revealed that the Omicron variant represented close to 100% of SARS-CoV-2 burden prior to the observed increase in newly diagnosed clinical cases throughout Alberta, which peaked two weeks later. These findings demonstrate that wastewater monitoring offers early and reliable population-level results for establishing the extent and spread of emerging pathogens including SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Alberta HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors